| ADR Ontology |
| ADR Term |
Polymyositis |
| ADR ID |
BADD_A03504 |
| ADR Hierarchy |
|
| Description |
Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9) [MeSH] |
| MedDRA Code |
10036102 |
| MeSH ID |
D017285
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Polymyositis | Polymyositis hemorrhagica | Polymyositis haemorrhagica | Polymyositides | Myositis, Multiple | Multiple Myositis | Myositides, Multiple | Polymyositis, Idiopathic | Idiopathic Polymyositides | Idiopathic Polymyositis | Polymyositides, Idiopathic | Polymyositis Ossificans | Ossificans, Polymyositis |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| HLA class II histocompatibility antigen, DRB1 beta chain | P01911 | Not Available |
|
| Drugs Leading to the ADR |
|
|
